Ashley Acheson
Concepts (227)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Substance-Related Disorders | 20 | 2020 | 671 | 4.600 |
Why?
| Impulsive Behavior | 20 | 2022 | 82 | 4.140 |
Why?
| Family Health | 10 | 2019 | 85 | 2.880 |
Why?
| Alcoholism | 12 | 2019 | 249 | 2.250 |
Why?
| Adolescent Behavior | 6 | 2020 | 113 | 2.090 |
Why?
| Risk-Taking | 8 | 2020 | 128 | 1.770 |
Why?
| Brain | 8 | 2023 | 1387 | 1.220 |
Why?
| Cannabis | 3 | 2019 | 147 | 1.040 |
Why?
| Stress, Psychological | 8 | 2019 | 270 | 1.030 |
Why?
| Attention | 5 | 2016 | 185 | 1.010 |
Why?
| Adolescent | 29 | 2023 | 6897 | 1.010 |
Why?
| Psychomotor Performance | 2 | 2015 | 156 | 0.970 |
Why?
| Memory, Short-Term | 5 | 2019 | 85 | 0.880 |
Why?
| Female | 49 | 2023 | 28441 | 0.750 |
Why?
| Male | 45 | 2023 | 27334 | 0.740 |
Why?
| Diffusion Tensor Imaging | 3 | 2022 | 97 | 0.730 |
Why?
| Young Adult | 20 | 2022 | 4318 | 0.720 |
Why?
| Hydrocortisone | 6 | 2019 | 124 | 0.680 |
Why?
| Cannabinoids | 1 | 2019 | 108 | 0.620 |
Why?
| Child of Impaired Parents | 2 | 2016 | 46 | 0.590 |
Why?
| Photic Stimulation | 2 | 2014 | 65 | 0.590 |
Why?
| Humans | 50 | 2023 | 54284 | 0.590 |
Why?
| Clinical Protocols | 1 | 2017 | 122 | 0.560 |
Why?
| Reward | 3 | 2011 | 123 | 0.560 |
Why?
| Memory | 2 | 2014 | 124 | 0.530 |
Why?
| Motor Cortex | 1 | 2015 | 18 | 0.530 |
Why?
| Corpus Striatum | 1 | 2015 | 66 | 0.520 |
Why?
| Prosencephalon | 1 | 2014 | 13 | 0.520 |
Why?
| Decision Making | 3 | 2014 | 290 | 0.510 |
Why?
| Antisocial Personality Disorder | 2 | 2012 | 18 | 0.510 |
Why?
| Longitudinal Studies | 7 | 2020 | 746 | 0.500 |
Why?
| Behavior | 2 | 2012 | 49 | 0.500 |
Why?
| Parietal Lobe | 1 | 2014 | 30 | 0.490 |
Why?
| Alcohol Drinking | 4 | 2019 | 259 | 0.490 |
Why?
| Phenotype | 1 | 2017 | 820 | 0.490 |
Why?
| Temporal Lobe | 1 | 2014 | 74 | 0.480 |
Why?
| Predictive Value of Tests | 3 | 2019 | 1048 | 0.460 |
Why?
| Gyrus Cinguli | 2 | 2014 | 29 | 0.460 |
Why?
| Child | 15 | 2023 | 7341 | 0.450 |
Why?
| Adult | 19 | 2023 | 14207 | 0.450 |
Why?
| Cognition | 4 | 2023 | 348 | 0.420 |
Why?
| Brain Mapping | 4 | 2015 | 250 | 0.400 |
Why?
| Risk Factors | 9 | 2020 | 3935 | 0.400 |
Why?
| Choice Behavior | 1 | 2011 | 95 | 0.360 |
Why?
| Family | 3 | 2017 | 193 | 0.360 |
Why?
| Caudate Nucleus | 1 | 2008 | 19 | 0.340 |
Why?
| Gambling | 1 | 2008 | 19 | 0.340 |
Why?
| Catechol O-Methyltransferase | 2 | 2019 | 11 | 0.330 |
Why?
| Adolescent Development | 2 | 2020 | 20 | 0.330 |
Why?
| Swine, Miniature | 2 | 2018 | 17 | 0.330 |
Why?
| Bupropion | 1 | 2008 | 30 | 0.320 |
Why?
| Gene-Environment Interaction | 3 | 2017 | 44 | 0.320 |
Why?
| Tacrolimus Binding Proteins | 2 | 2019 | 6 | 0.320 |
Why?
| Temperament | 3 | 2017 | 23 | 0.310 |
Why?
| Dopamine Uptake Inhibitors | 1 | 2008 | 61 | 0.310 |
Why?
| Diffusion Magnetic Resonance Imaging | 3 | 2018 | 126 | 0.300 |
Why?
| Sleep Deprivation | 1 | 2007 | 16 | 0.300 |
Why?
| Genetic Predisposition to Disease | 3 | 2015 | 570 | 0.300 |
Why?
| Nucleus Accumbens | 1 | 2006 | 22 | 0.290 |
Why?
| Diazepam | 1 | 2006 | 18 | 0.290 |
Why?
| Double-Blind Method | 6 | 2018 | 742 | 0.290 |
Why?
| Reaction Time | 2 | 2006 | 227 | 0.280 |
Why?
| Ethanol | 4 | 2012 | 322 | 0.280 |
Why?
| Oklahoma | 5 | 2015 | 30 | 0.280 |
Why?
| Aspartic Acid | 2 | 2015 | 48 | 0.260 |
Why?
| Naltrexone | 3 | 2018 | 62 | 0.250 |
Why?
| Brain Injuries | 1 | 2006 | 183 | 0.250 |
Why?
| Nicotine | 1 | 2006 | 207 | 0.250 |
Why?
| Polymorphism, Single Nucleotide | 3 | 2017 | 552 | 0.240 |
Why?
| Child Behavior | 2 | 2017 | 114 | 0.240 |
Why?
| Child Abuse | 2 | 2019 | 170 | 0.230 |
Why?
| Life Change Events | 2 | 2014 | 41 | 0.230 |
Why?
| Risk Assessment | 3 | 2020 | 1361 | 0.210 |
Why?
| Analgesics, Opioid | 3 | 2022 | 501 | 0.210 |
Why?
| Psychotic Disorders | 1 | 2023 | 144 | 0.210 |
Why?
| Narcotic Antagonists | 3 | 2018 | 127 | 0.200 |
Why?
| Principal Component Analysis | 2 | 2019 | 71 | 0.200 |
Why?
| Magnetic Resonance Imaging | 4 | 2022 | 1604 | 0.200 |
Why?
| Schizophrenia | 1 | 2023 | 276 | 0.200 |
Why?
| Polymorphism, Genetic | 2 | 2019 | 193 | 0.190 |
Why?
| Vulnerable Populations | 1 | 2020 | 44 | 0.190 |
Why?
| Reproducibility of Results | 4 | 2019 | 1304 | 0.190 |
Why?
| Heart Rate | 3 | 2019 | 357 | 0.180 |
Why?
| Alcohol-Related Disorders | 1 | 2020 | 55 | 0.180 |
Why?
| Psychomotor Agitation | 1 | 2020 | 53 | 0.180 |
Why?
| Disease Resistance | 1 | 2019 | 7 | 0.180 |
Why?
| Psychopharmacology | 1 | 2019 | 5 | 0.180 |
Why?
| Adult Survivors of Child Abuse | 2 | 2018 | 19 | 0.180 |
Why?
| Attention Deficit Disorder with Hyperactivity | 2 | 2016 | 231 | 0.180 |
Why?
| Anisotropy | 2 | 2022 | 63 | 0.180 |
Why?
| Cerebral Cortex | 2 | 2012 | 234 | 0.170 |
Why?
| Psychiatric Status Rating Scales | 4 | 2015 | 346 | 0.170 |
Why?
| Contraceptive Agents | 1 | 2019 | 17 | 0.170 |
Why?
| Behavior, Addictive | 1 | 2019 | 58 | 0.170 |
Why?
| Central Nervous System Stimulants | 2 | 2016 | 255 | 0.170 |
Why?
| Circadian Rhythm | 1 | 2019 | 85 | 0.170 |
Why?
| Arousal | 1 | 2018 | 106 | 0.160 |
Why?
| Personality Assessment | 1 | 2018 | 16 | 0.160 |
Why?
| Case-Control Studies | 3 | 2022 | 1228 | 0.160 |
Why?
| Antipsychotic Agents | 1 | 2020 | 247 | 0.160 |
Why?
| Regression Analysis | 2 | 2019 | 445 | 0.150 |
Why?
| Stroop Test | 2 | 2014 | 10 | 0.150 |
Why?
| Adaptation, Psychological | 1 | 2018 | 244 | 0.150 |
Why?
| Cohort Studies | 2 | 2014 | 1543 | 0.150 |
Why?
| Models, Animal | 1 | 2017 | 255 | 0.150 |
Why?
| Conduct Disorder | 1 | 2016 | 17 | 0.150 |
Why?
| Affect | 2 | 2008 | 104 | 0.150 |
Why?
| Image Processing, Computer-Assisted | 2 | 2017 | 256 | 0.150 |
Why?
| Drug Users | 1 | 2016 | 21 | 0.140 |
Why?
| Smoking | 2 | 2012 | 556 | 0.140 |
Why?
| Emergency Service, Hospital | 1 | 2020 | 539 | 0.140 |
Why?
| Methylphenidate | 1 | 2016 | 94 | 0.140 |
Why?
| Time Factors | 4 | 2012 | 3213 | 0.130 |
Why?
| Genotype | 4 | 2019 | 599 | 0.130 |
Why?
| Socioeconomic Factors | 1 | 2017 | 642 | 0.130 |
Why?
| Receptors, Opioid, mu | 1 | 2015 | 47 | 0.130 |
Why?
| Breath Tests | 2 | 2012 | 44 | 0.130 |
Why?
| Neural Pathways | 1 | 2015 | 97 | 0.130 |
Why?
| Animals | 8 | 2019 | 14385 | 0.130 |
Why?
| Signal Processing, Computer-Assisted | 1 | 2015 | 92 | 0.130 |
Why?
| Parent-Child Relations | 1 | 2015 | 71 | 0.130 |
Why?
| Executive Function | 1 | 2015 | 80 | 0.120 |
Why?
| Functional Neuroimaging | 1 | 2014 | 25 | 0.120 |
Why?
| Psychological Tests | 1 | 2014 | 54 | 0.120 |
Why?
| Choline | 1 | 2014 | 63 | 0.120 |
Why?
| Frontal Lobe | 1 | 2014 | 56 | 0.120 |
Why?
| Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 51 | 0.120 |
Why?
| Follow-Up Studies | 2 | 2017 | 2387 | 0.120 |
Why?
| Cognition Disorders | 2 | 2012 | 240 | 0.120 |
Why?
| Prefrontal Cortex | 1 | 2014 | 89 | 0.120 |
Why?
| Risk | 1 | 2014 | 343 | 0.120 |
Why?
| Drug-Seeking Behavior | 1 | 2012 | 5 | 0.110 |
Why?
| Social Adjustment | 1 | 2012 | 31 | 0.110 |
Why?
| Alcoholic Intoxication | 1 | 2012 | 24 | 0.110 |
Why?
| Substance Abuse Detection | 1 | 2012 | 92 | 0.100 |
Why?
| Binge Drinking | 1 | 2012 | 28 | 0.100 |
Why?
| Prospective Studies | 2 | 2015 | 2604 | 0.100 |
Why?
| Temperance | 1 | 2011 | 10 | 0.100 |
Why?
| Databases, Factual | 2 | 2012 | 684 | 0.100 |
Why?
| Intelligence Tests | 1 | 2011 | 44 | 0.100 |
Why?
| Anxiety | 1 | 2012 | 279 | 0.100 |
Why?
| Central Nervous System Depressants | 1 | 2011 | 78 | 0.100 |
Why?
| Drug Interactions | 3 | 2006 | 206 | 0.090 |
Why?
| Suicide, Attempted | 1 | 2011 | 73 | 0.090 |
Why?
| Rats, Sprague-Dawley | 4 | 2006 | 1663 | 0.090 |
Why?
| Behavior, Animal | 2 | 2006 | 200 | 0.080 |
Why?
| Stress Disorders, Post-Traumatic | 1 | 2012 | 394 | 0.080 |
Why?
| Games, Experimental | 1 | 2007 | 11 | 0.080 |
Why?
| Middle Aged | 3 | 2008 | 13088 | 0.080 |
Why?
| Saliva | 2 | 2019 | 63 | 0.070 |
Why?
| Pregnancy | 3 | 2023 | 2620 | 0.070 |
Why?
| Quinolinic Acid | 1 | 2006 | 2 | 0.070 |
Why?
| Phosphopyruvate Hydratase | 1 | 2006 | 7 | 0.070 |
Why?
| Swine | 2 | 2018 | 431 | 0.070 |
Why?
| Rats | 4 | 2006 | 3415 | 0.070 |
Why?
| Dose-Response Relationship, Drug | 2 | 2008 | 1476 | 0.070 |
Why?
| Health Behavior | 1 | 2008 | 277 | 0.070 |
Why?
| Reference Values | 1 | 2007 | 354 | 0.070 |
Why?
| United States | 1 | 2017 | 5217 | 0.070 |
Why?
| Reinforcement Schedule | 1 | 2006 | 64 | 0.070 |
Why?
| Probability | 1 | 2006 | 176 | 0.070 |
Why?
| Conditioning, Operant | 1 | 2006 | 106 | 0.070 |
Why?
| Neuropsychological Tests | 1 | 2007 | 363 | 0.070 |
Why?
| Indoles | 1 | 2008 | 289 | 0.070 |
Why?
| Personality Inventory | 2 | 2015 | 50 | 0.070 |
Why?
| Motor Activity | 1 | 2006 | 247 | 0.060 |
Why?
| Smoking Cessation | 1 | 2008 | 316 | 0.060 |
Why?
| Body Weight | 1 | 2006 | 578 | 0.060 |
Why?
| Interpersonal Relations | 2 | 2016 | 117 | 0.060 |
Why?
| Morphine | 1 | 2004 | 96 | 0.060 |
Why?
| Comorbidity | 2 | 2017 | 663 | 0.060 |
Why?
| Sex Factors | 1 | 2006 | 767 | 0.060 |
Why?
| Texas | 2 | 2014 | 160 | 0.060 |
Why?
| Immunohistochemistry | 1 | 2006 | 1089 | 0.060 |
Why?
| Luteinizing Hormone | 1 | 2002 | 14 | 0.060 |
Why?
| Prenatal Exposure Delayed Effects | 1 | 2005 | 173 | 0.060 |
Why?
| Macaca mulatta | 1 | 2002 | 106 | 0.050 |
Why?
| Pregnancy Trimester, Third | 1 | 2022 | 66 | 0.050 |
Why?
| Buprenorphine | 1 | 2004 | 132 | 0.050 |
Why?
| Growth Hormone | 1 | 2002 | 78 | 0.050 |
Why?
| Age Factors | 2 | 2018 | 1198 | 0.050 |
Why?
| Emotions | 2 | 2012 | 168 | 0.050 |
Why?
| Fetus | 1 | 2022 | 227 | 0.050 |
Why?
| Gestational Age | 1 | 2022 | 435 | 0.050 |
Why?
| Ultrasonography, Prenatal | 1 | 2022 | 177 | 0.050 |
Why?
| Controlled Clinical Trials as Topic | 1 | 2020 | 21 | 0.050 |
Why?
| Injections, Intramuscular | 1 | 2020 | 50 | 0.050 |
Why?
| Speech | 1 | 2019 | 55 | 0.040 |
Why?
| Alleles | 1 | 2019 | 277 | 0.040 |
Why?
| Puberty | 1 | 2018 | 20 | 0.040 |
Why?
| Sexual Maturation | 1 | 2017 | 13 | 0.040 |
Why?
| Cross-Over Studies | 1 | 2018 | 250 | 0.040 |
Why?
| Linear Models | 1 | 2018 | 309 | 0.040 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2020 | 596 | 0.040 |
Why?
| Southwestern United States | 1 | 2017 | 21 | 0.040 |
Why?
| Sensation | 1 | 2017 | 15 | 0.040 |
Why?
| Psychometrics | 1 | 2018 | 241 | 0.040 |
Why?
| Aging | 1 | 2002 | 784 | 0.040 |
Why?
| Mathematical Concepts | 1 | 2015 | 2 | 0.030 |
Why?
| Social Perception | 1 | 2015 | 32 | 0.030 |
Why?
| Age of Onset | 1 | 2015 | 117 | 0.030 |
Why?
| Random Allocation | 1 | 2015 | 312 | 0.030 |
Why?
| Mood Disorders | 1 | 2014 | 63 | 0.030 |
Why?
| Residence Characteristics | 1 | 2015 | 166 | 0.030 |
Why?
| Infant | 1 | 2022 | 3817 | 0.030 |
Why?
| Mothers | 1 | 2016 | 247 | 0.030 |
Why?
| Sex Characteristics | 1 | 2015 | 214 | 0.030 |
Why?
| Checklist | 1 | 2012 | 36 | 0.030 |
Why?
| Sex Distribution | 1 | 2012 | 158 | 0.030 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 322 | 0.020 |
Why?
| Sensitivity and Specificity | 1 | 2012 | 923 | 0.020 |
Why?
| Mental Disorders | 1 | 2014 | 451 | 0.020 |
Why?
| Cross-Sectional Studies | 1 | 2014 | 1693 | 0.020 |
Why?
| Skin | 1 | 2012 | 469 | 0.020 |
Why?
| Depression | 1 | 2011 | 595 | 0.020 |
Why?
| Rats, Long-Evans | 1 | 2004 | 29 | 0.020 |
Why?
| Taste | 1 | 2004 | 37 | 0.020 |
Why?
| Species Specificity | 1 | 2004 | 205 | 0.010 |
Why?
| Administration, Oral | 1 | 2004 | 459 | 0.010 |
Why?
| Periodicity | 1 | 2002 | 29 | 0.010 |
Why?
| Growth Hormone-Releasing Hormone | 1 | 2002 | 22 | 0.010 |
Why?
| Progesterone | 1 | 2002 | 69 | 0.010 |
Why?
| Analysis of Variance | 1 | 2004 | 635 | 0.010 |
Why?
| Insulin-Like Growth Factor I | 1 | 2002 | 137 | 0.010 |
Why?
| Oligopeptides | 1 | 2002 | 95 | 0.010 |
Why?
| Estradiol | 1 | 2002 | 219 | 0.010 |
Why?
| Disease Models, Animal | 1 | 2005 | 1639 | 0.010 |
Why?
|
|
Acheson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|